(Q53174548)

English

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

scientific article published on 15 February 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

phase II clinical trial

0 references

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

Emanuele Angelucci

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Francesco Merli

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maurizio Bonfichi

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Armando Santoro

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Monica Balzarotti

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ercole Brusamolino

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Angelo Michele Carella

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Eleonora Russo

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Angelagiovanna Congiu

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Manuel Gotti

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Stefania Massidda

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Barbara Botto

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Giorgia Annechini

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Alessandro Re

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Vittorio Ruggero Zilioli

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Flavia Salvi

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Caterina Stelitano

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Marcello Rodari

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Roberta Murru

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Massimo Magagnoli

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Antonella Anastasia

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Rita Mazza

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Laura Giordano

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

15 February 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

57

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

2375-2381

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Enhancement of vascular progenitor potential by protein kinase A through dual induction of Flk-1 and Neuropilin-1.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Revised response criteria for malignant lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53174548&oldid=1520979962"